Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
It is the objective of this MRD trial to investigate pharmacokinetics, pharmcodynamics, safety and tolerability of rising doses BI 691751 over a treatment period of 14 days to support the further clinical development of this LTA4H-inhibitor. Special emphasis will be given to detect potential effects of BI 691751 on heart rate.
Epistemonikos ID: 226693e229949f8562ffad67033fbc9c58cb152e
First added on: May 11, 2024